COVID-19 Antibody Cocktail Sweetens Regeneron’s Growth Story
With REGEN-COV in the mix, Regeneron recorded 51% total revenue growth during Q3, including partnership revenue from Roche, but the product’s long-term viability remains in question.
You may also be interested in...
Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.
Could Prevention Data Give REGEN-COV Competitive Leg Up?
The UK becomes the first country to grant a marketing authorization for the oral treatment which could help cut hospitalizations and deaths by half.